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A B S T R A C T   
Monitoring of chemical water quality is extremely challenging due to the large variety of compounds and the 
presence of biologically active compounds with unknown chemical identity. Previously, we developed a high 
resolution Effect-Directed Analysis (EDA) platform that combines liquid chromatography with high resolution 
mass spectrometry and parallel bioassay detection. In this study, the platform is combined with CALUX bioassays 
for (anti)androgenic, estrogenic and glucocorticoid activities, and the performance of the platform is evaluated. 
It appeared to render very repeatable results, with high recoveries of spiked compounds and high consistency 
between the mass spectrometric and bioassay results. Application of the platform to wastewater treatment plant 
effluent and surface water samples led to the identification of several compounds contributing to the measured 
activities. Eventually, a workflow is proposed for the application of the platform in a routine monitoring context. 
The workflow divides the platform into four phases, of which one to all can be performed depending on the 
research question and the results obtained. This allows one to make a balance between the effort put into the 
platform and the certainty and depth by which active compounds will be identified. The EDA platform is a 
valuable tool to identify unknown bioactive compounds, both in an academic setting as in the context of leg-
islative, governmental or routine monitoring.   
1. Introduction 
Our modern society uses thousands of different organic chemical 
compounds that end up in the water cycle (Houtman, 2010; Stefanakis 
AIB, 2015) via discharge of sewage, agricultural and industrial waste 
and often incomplete removal in wastewater treatment (Petrovic et al., 
2006, 2003). This is worrying, as these compounds might adversely 
affect public health via drinking water (DW) prepared from surface 
water and the health of ecosystems. Proper monitoring of chemical 
water quality is extremely challenging due to the large variety of 
compounds that should be analysed and due to the presence of many 
biologically active compounds with unknown chemical identity 
(Houtman, 2010; van Wezel et al., 2010; Weiss et al., 2011). 
Mechanism-based in vitro bioassays – biological test systems that 
directly estimate a specific biological effect in a sample - are used more 
and more to investigate compounds with biological, possibly toxic ac-
tivities (Schriks MB et al., 2015). Bioassays are important tools for 
water boards to monitor chemical water quality in their catchments and 
for DW companies to survey the chemical water quality in their sources 
for the preparation of DW (Escher et al., 2014; Houtman et al., 2018;  
Luigi, 2011; van der Oost et al., 2017a). 
Nowadays, the panel of effects for which bioassays have been de-
veloped has grown considerably. As biological pathways that are 
identified for humans and ecology are numerous, certain molecular key 
events of adverse outcome pathways of effects (Ankley et al., 2010) 
have been pinpointed that should ideally be assessed by bioassays to 
cover the most relevant health endpoints in water samples, for both 
human health (Schriks MB et al., 2015) and aquatic ecology (Escher 
et al., 2018; Neale et al., 2017; van der Oost et al., 2017b). These in-
clude xenobiotic metabolism, reactive modes of action, cytotoxicity, 
developmental toxicity and endocrine disruption. If bioassays are ap-
plied for water quality assessment it should be decided which level of 
response is considered to indicate a human or environmental risk. To 
this purpose suites of effect-based ‘trigger values’ (EBT) have been de-
rived in recent years (Escher et al., 2018; van der Oost et al., 2017b;  
Brand et al., 2013). These trigger values differentiate between low risks 
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for adverse effects if bioassay responses are below EBT, and increased 
risks for adverse effects on human or ecosystem health if bioassay re-
sponses exceed the EBT. 
Endocrine disruption is an important endpoint as the presence of 
endocrine disrupting compounds –able to mimic or antagonize steroid 
hormonal action in the body – in surface waters may cause adverse 
effects on aquatic organisms (Sumpter and Jobling, 2013; Jobling et al., 
1998). There is also concern for human health as there are indications 
that exposure to endocrine disrupting compounds (EDCs) might play a 
role in the aetiology of health problems like reduced fertility, obesitas 
and type II diabetes mellitus (Kabir et al., 2015; Touraud et al., 2011;  
Heindel et al., 2015; Ehrlich et al., 2016). EDCs include natural hor-
mones, human and veterinary pharmaceuticals, metabolites thereof and 
many industrial compounds able to interfere with hormonal action, 
such as hormone receptor activation (Sumpter, 2005). 
Although estrogens and androgens in the environment have re-
ceived most research attention, awareness is growing for other hor-
monal (and corresponding antagonistic) activities, as also compounds 
with e.g. glucocorticoids, and progestogenic activities are being used by 
humans and livestock and consequently released into the environment. 
The presence of EDC in water can be determined chemically or 
biologically by different reporter gene bioassays (Escher et al., 2014;  
Macova et al., 2011; Neale et al., 2012; Van der Linden et al., 2008). 
Once activity is found in the bioassay, the identity of the causative 
compounds is often required to enable risk assessment and source 
tracking of the EDC. However, as bioassays are usually performed using 
extracts of environmental samples, they assess the total activity of the 
whole mixture without separating compounds contributing to the ac-
tivity and determining their chemical identity. This is a principal dif-
ference from chemical analyses that use chromatographic separation of 
compounds before detecting them one by one. 
Effect-directed analysis (EDA) is a powerful tool to identify the 
drivers of bioassay activity in complex environmental samples. It 
combines bioassay analysis with chromatographic separation (fractio-
nation) and chemical analysis of active fractions (Brack et al., 2016;  
Houtman et al., 2011). In the past, the successful application of EDA 
was often hampered by limited chromatographic resolution and iden-
tifying power (Houtman et al., 2011). To overcome this, a high 
Fig. 1. Flow diagram of the experimental approach of the high resolution Effect-Directed Analysis (EDA) platform for water samples. Colourless blocks refer to 
sample treatment steps, yellow blocks represent bioassay measurements, green blocks represent chemical analyses. A schematic representation of the platform with 
an explanation for each step is provided in the Supplemental Information Figure S1. 
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resolution EDA platform was developed applying high resolution frac-
tionation and LC–MS identification (Jonker et al., 2015). The platform 
allows construction of bioassay chromatograms that can directly be 
correlated to MS chromatograms recorded in parallel, allowing 
straightforward pinpointing of accurate masses of active compounds. 
The applicability of the novel platform was demonstrated in studies 
published by Zwart et al. (2020), 2018 and Jonker et al. (2016). 
The present study has three main objectives:  
1 To evaluate the method performance of the HT-EDA-platform. The 
platform appeared to be powerful in the aforementioned demon-
stration studies (Jonker et al., 2016, 2019; Kabir et al., 2015). 
However, additional evidence of the robustness of the platform is 
needed before it can be applied in a more structural, legislative or 
governmental context. Therefore, repeatability, recovery, detection 
limits and performance of negative and positive controls were as-
sessed.  
2 To apply the platform to different compartments of the water cycle, 
i.e. surface water samples from four abstraction points for the pre-
paration of drinking water and effluent of a wastewater treatment 
plant (WWTP). The drivers of (anti-)androgenic, estrogenic and 
glucocorticoid activities in these samples were investigated.  
3 To derive a workflow for the application of the platform in a context 
of legislative, governmental or routine monitoring. 
2. Materials and methods 
2.1. General procedure HT-EDA platform 
A schematic representation of the experimental procedure of the 
EDA is provided in Fig. 1. 
2.1.1. Extraction 
Surface water samples and WWTP effluent were collected (for de-
tails, see section 2.3.1) and control samples were composed (see section  
2.2.1). Samples were extracted using Oasis HLB solid phase extraction 
(SPE) cartridges in portions of 1 L (surface water and control samples) 
or 0.4 L (WWTP effluent) per cartridge. Compounds were eluted with 
1:1 methanol (MeOH) and ethylacetate as described in (Houtman et al., 
2018). For each sample, three extracts were prepared in this way. The 
three extracts were mixed and split again in three equal parts. Extracts 
(portions equivalent to 1 L for surface water or control samples; or to 
0.4 L for WWTP effluent) were evaporated and dissolved in 50 μL di-
methyl sulfoxide (DMSO, spectrophotometric grade, Acros, Geel, Bel-
gium) for the analysis of the total activity in the unfractionated extracts 
(left part of Fig. 1). The second part was evaporated and dissolved in 
700 μL milliQ water with 5 % MeOH for fractionation (in the centre of  
Fig. 1). The third part was stored at −20 °C for future use (shown at the 
right in Fig. 1). 
2.1.2. Bioassay measurements in unfractionated extracts 
Androgenic, estrogenic and glucocorticoid activities in un-
fractionated extracts were measured with the AR (agonistic), anti-AR 
(antagonistic mode), ERα and GR CALUX reporter gene assays 
(BioDetection Systems B.V., Amsterdam, the Netherlands) as described 
previously (Houtman et al., 2018; Van der Linden et al., 2008) and as 
laid down in the protocols of the supplier. We used the limits of 
quantification (LOQ) and limits of detection (LOD) for the analysis of 
unfractionated water extracts as derived and provided by BioDetections 
Systems. They are given in Table S1.The reference compounds were 
dihydrotestosterone (DHT), flutamide (Flt), 17β-estradiol (E2) and 
dexamethasone (Dex) respectively. A 10 point calibration curve of the 
reference compound was included on each plate. A sigmoidal standard 
curve (y = Bottom + (Top-Bottom)/(1 + 10^((LogEC50-x)*Hill Slope)) 
was fitted through the calibration curve using the software package 
GraphPad Prism 7.03 (www.graphpad.com) with y representing the 
luciferase activity, x the concentration of the reference compound and 
EC50 the half-maximum effective concentration. Responses of dilutions 
of the water extracts giving response between the limit of detection 
(LOD) and the EC50 were interpolated in the standard curve and re-
sponses expressed as equivalents of the reference compounds per litre 
water. 
2.1.3. Fractionation 
Chromatographic separation was performed by injecting 250 μL of 
the second extract part on a Waters Acquity UPLC C18 column ac-
cording to (Zwart et al., 2020), with the following adaptations. The 
gradient changed from 5% MeOH in MilliQ-water at t = 0 min to 100 % 
MeOH in 23 min. Post column, the eluent was split into two portions. 
Two third was led to a FractioMate™ fraction collector (SPARKHolland 
& VU, Emmen & Amsterdam, the Netherlands,) (Jonker et al., 2019) 
and one third to an Impact II QTOF mass spectrometer (Bruker Dal-
tonics, Billerica, MA, USA). Fractions were collected at 4.8 s (288 
fractions) intervals in transparent PS 384-well plates (Greiner Bio-One) 
to record the bioassay chromatograms (CALUX activities in the frac-
tions). Prior to the fractionation, the 384-well plates were filled with 
4 μL 10 % DMSO in milliQ water per well to serve as a keeper during 
solvent evaporation. The well plates containing the 288 collected 
fractions per sample extract were dried in a Centrivap concentrator for 
5 h at 25 °C under vacuum until dryness and then stored at −20 °C. 
2.1.4. Recording bioassay chromatograms with fractionated extracts 
The cell suspensions (34 μL; ∼105 cells/mL) were seeded in white 
384 well plates with transparent colourless bottom (Greiner Bio-one, 
Frickenhausen, Germany) and incubated for 24 h at 37 °C and 5 % CO2. 
The two outer rows were kept empty. The medium was removed and 
replaced with 24 μL assay medium. The assay medium used for plates 
seeded with AR CALUX cells for the anti-androgenicity testing was 
spiked with 3.4 × 10−7 M DHT in the well, to achieve a background 
level of DHT at approximately EC40 during exposure. 
At the day of exposure, plates containing the fractions were thawed 
and fractions were redissolved in 50 μL assay medium containing 0.34 
% DMSO. Each well containing a fraction was analysed with each re-
porter gene assay. Therefore, 10 μL of each fraction were added to the 
24 μL medium in each well of the well plates of the different bioassays 
(AR, anti-AR, ER and GR CALUX). In this way, exposure was performed 
at a final DMSO concentration of 0.1 %. In order to save enough wells 
on each cell plate to include a calibration curve, the fractions were 
divided over two well plates per bioassay. Calibration curves (10 con-
centrations covering the full concentration response ranges) were in-
cluded in triplicate on each well plate. 
Well plates were exposed for 24 h and lysed with 17 μL lysis buffer 
(Houtman et al., 2004a) added to each well. The luminescence was 
measured with a luminometer (Tristar LB941, Berthold, Vilvoorde, 
Belgium). The luminescence was expressed as percentage of the max-
imum luminescence of the calibration curve and plotted as function of 
the retention time (RT) of each spotted fraction, resulting in the 
bioassay chromatogram. 
2.1.5. MS analysis and identification 
MS analysis and interpretation (non-target screening (NTS)) was 
performed on an Impact II QTOF mass spectrometer (Bruker Daltonics, 
Billerica, MA, USA) as described in (Zwart et al., 2020). Each sample was 
analysed twice; the first time in positive and the second time in negative 
ionisation mode. Data were recorded using data independent acquisition 
(broad band collision induced dissociation). MS data recorded within 
time windows between 0.2 min before and after peaks in the bioassay 
chromatograms were interpreted to identify compounds responsible for 
the observed activity. Extracted ion chromatograms (EIC) with accurate 
masses ( ± 5 m Da, full scan) were plotted for features. Criteria for as-
signing molecular formula and/or database entries to features were 
isotopic pattern matching expressed as mSigma score, and an absolute 
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mass accuracy window of 1 m Da, resulting in varying ppm accuracies 
across the mass range: 4 ppm at m/z 250, and 1 ppm at m/z 1000. RT and 
created fragments were derived from the EIC. The NORMAN Massbank 
High Resolution Mass spectral Database (https://massbank.eu/ 
MassBank), and MzCloud Advanced Mass Spectral database (https:// 
www.mzcloud.org) were searched for the features, to verify their iden-
tification according to the spectrum. If compounds were not available in 
these databases, fragments were uploaded in MetFrag (https://msbi.ipb- 
halle.de/MetFragBeta; 2 ppm) or Fragmentation Explorer in DataAna-
lysis (Bruker Daltonics, Billerica, MA, USA) to search for hits. 
2.2. Evaluation of method performance 
The performance of the EDA method was evaluated using positive 
and negative control samples, field samples and a spiking mixture. An 
overview of the test setup and the specific purposes of each step is given 
in Table S2. 
2.2.1. Bioassay testing of unfractionated extracts 
Positive (spiked clean water) and negative control samples (un-
spiked clean water, serving as procedure blank) were used to test the 
recovery of the activity from unfractionated extracts, and the repeat-
ability of testing in triplicate 
The positive controls were prepared by in triplicate spiking of 1 L 
water (HPLC quality, J.T. Baker, Fischer Scientific, Amsterdam, the 
Netherlands) with 50 μL of a spiking mixture in DMSO of the agonistic 
reference compounds of the ER CALUX (E2 1.8 × 10−8 M in the spiking 
mixture), AR CALUX (DHT, 1.60 × 10-7M), and GR CALUX (Dex 
1.3 × 10-5 M), that would lead to concentrations in water of 245 pg E2/ 
L, 2.32 ng DHT/L and 245 ng Dex/L at 100 % recovery. Three separate 
portions of 1 L water were spiked with 50 μL of 2.84 × 10-3M Flt in 
DMSO, leading to a concentration of 39.2 μg Flt/L water at 100 % re-
covery that was tested in the anti-AR CALUX. The antagonistic re-
ference compound Flt was spiked separately from the agonistic re-
ference compounds because spiked to the same bottles, DHT and Flt 
would mask each other’s activities and recoveries would seem lower 
than they would be in reality. 
Recovery of the activity was assessed by the measurement of the 
activity in the CALUX bioassays in the unfractionated extracts and ex-
pressing the measured activity as percentage of the activity at 100 % 
recovery. Coefficients of variation (CV) were calculated as: SD of a 
triplicate value / average of the triplicate value * 100 %. 
The negative controls consisted of 3 × 1 L unspiked water of HPLC 
quality. 
The repeatability of the CALUX analysis of a field sample was tested 
by in threefold sampling and processing of a surface water sample from 
the Lek Channel in the Netherlands The third replicate also served as 
Rhine water sample in the second goal of the study, see section 2.3.1). 
2.2.2. Bioassay chromatograms (fractionated extracts) 
Positive and negative samples were prepared in monoplo as de-
scribed for unfractionated testing, with the difference that for the po-
sitive control now both agonistic and antagonistic reference compounds 
were spiked in the same sample, as they would be separated chroma-
tographically during the fractionation. The control samples were ana-
lysed with the EDA platform as described in sections 2.1.3 to 2.1.5. The 
positive control served to test the recovery of the correct peaks in the 
bioassay chromatogram. 
The negative control served to determine the background signal of 
the baseline and to calculate the minimum reporting limits (MRL) of the 
bioassay chromatograms.). The MRLs of the bioassay chromatograms for 
the 3 agonistic bioassays were calculated from the responses of all the 
fractions of the negative control sample as: average of the responses of 
the fractions of the negative control + 3x standard deviation (SD) of 
these responses. Due to the higher biological variation in the baseline (at 
∼EC40) of the anti-AR CALUX the same formula to calculate the MRL as 
for the agonistic assays would generate an unworkable MRL. Therefore 
the MRL for this assay was set as the average response minus 2x SD 
(approximately equalling 1/3 of the average response of the baseline). 
In triplicate prepared extracts of 1 L portions of surface water from 
the Lek Channel were fractionated and bioassay chromatograms were 
recorded as described in 2.2.1, 2.1.3 and 2.1.4 to test the repeatability 
of the recording of bioassay chromatograms. 
2.2.3. Consistency between bioassay chromatograms and MS results 
Consistency between retention times of the peaks in the bioassay 
chromatogram and in the MS was investigated by in triplicate analysis 
of a spiking mixture containing 31 natural and synthetic androgens, 
estrogens, (gluco)corticoids and progestogens on the EDA platform (see 
Table S3). An aliquot of 12.5 μL of a 1 mg/L stock solution in MeOH was 
dissolved in 250 μL MQ and injected in triplicate on the UPLC-QToF-MS 
to determine RTs on the MS. Then, 12.5 μL portions of a 5 μg/L dilution 
of the stock solution were dissolved in 250 μL MQ and injected in tri-
plicate (experiment a, b, and c) on the UPLC and fractionated to record 
bioassay chromatograms in AR, ER and GR CALUX. 
2.3. Application to field water samples 
2.3.1. Sampling and sample preparation 
Surface water grab samples were collected in 1 L green glass bottles 
with PFTE-PE lined lids (Identipack, Someren, The Netherlands) pre- 
rinsed with ethyl acetate at abstraction points used by Dutch DW 
companies at the rivers Meuse (Enclosed Meuse) and Rhine (Lek 
Channel), Lake IJssel and a reclaimed land area Bethune Polder 
(Reclaimed Land). For a detailed description of the sites, see (Houtman 
et al., 2019). In addition, a 24 h volume proportional effluent sample 
was taken from a WWTP (for details, see description plant A in (9)). 
Samples were stored at 4 °C and processed with the EDA platform 
within one week. For surface water samples 3x a portion of 1 L water 
was extracted, for the effluent 3 × 0.4 L. In this way, one portion of 
extract of each sample served for bioassay analysis of the un-
fractionated extract, one for the EDA and one portion of extract was 
stored at −20 °C for future use. 
In order to interpret the results of surface water and WWTP effluent 
in terms of risk assessment, the effects of the unfractionated extracts in 
the bioassays are compared to EBT values as proposed by Brand et al. 
(2013); Escher et al. (2018), 2015, Jarošová et al. (2014), Van der Oost 
et al. (van der Oost et al., 2017b) and Béen et al. (in preparation). 
Results of WWTP effluent were compared with ETBs for ecology, those 
of surface water with EBTs for ecology and, because of the function as 
drinking water source, with ETBs for human health as well. 
2.3.2. Identity confirmation 
Analytical standards of tentatively identified compounds were 
purchased in order to confirm their identity. A solution of 10 μg/L in 
5% MeOH (injection volume 250 μL) of the standard was injected on 
the UPLC-QToF-MS to verify if the tentatively identified compound 
indeed eluted at the same RT as that of the peak in the bioassay chro-
matogram. 
Series of 10 dilutions of identified candidate compounds were pre-
pared in DMSO. These series were tested in triplicate in the anti-andro-
genic CALUX. The dilution series were also tested with the cytotox 
CALUX bioassay according to (van der Linden et al., 2014) to check if the 
anti-androgenic effect of the compounds was due to general cytotoxicity 
instead of genuine antagonistic action on the androgen receptor. If a 
compound was active, a sigmoidal curve (for the equation, see section  
2.1.2) was fitted through the data to derive the EC50. The relative po-
tency (REP) compared of the reference compound was calculated as:  
REP(candidate compound) = EC50(reference compound)/EC50(candidate compound).                                                                                                   
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3. Results and discussion 
3.1. Evaluation of the method performance 
3.1.1. CALUX analysis in unfractionated extracts 
The (anti-)androgenic, estrogenic and glucocorticoid activities 
measured in the unfractionated control samples are presented in  
Table 1. The activities in the negative control samples were below the 
limit of detection, indicating that no contamination with active sub-
stances had occurred during the experimental procedures. The re-
coveries of the agonistic and antagonistic activities in the positive 
controls were all > 70 % of the spiked concentrations, indicating that 
the used extraction procedure recovers steroid hormone-like and an-
tagonistic compounds, and with repeatabilities between 17 % (ERα) 
and 25 % (anti-AR and GR). 
The repeatability of anti-androgenic activity in the triplicate water 
samples from the Lek Channel (CV 21 %) was comparable with that of 
the positive control (CV 25 %, that contained much less matrix). The 
samples showed no androgenic, estrogenic or glucocorticoid activity, 
therefore the repeatability for these effects could not be judged. 
3.1.2. Bioassay chromatograms 
The bioassay chromatograms of the negative and positive controls 
can be found in the SI (Fig. S2). As expected, there were no peaks in the 
bioassay chromatograms of the negative control. All reference com-
pounds were detected in the positive controls as single sharp peaks in 
the bioassay chromatograms. DHT and Flt could be detected as in-
dividual peaks and there was no mutual masking of their activities, as 
would have been the case in an unfractionated extract in which they 
would have been present together. This indicates the added value of 
fractionation if both agonistic and antagonistic compounds for a certain 
bioassay are present in a sample. The triplicate bioassay chromato-
grams of the anti-androgenic activity in the Lek Channel sample are 
presented in Fig. S3. Due to the addition of DHT to the exposure 
medium of the anti-AR CALUX, the baseline of the bioassay chroma-
tograms of this assay was higher and showed higher biological variation 
than seen in the AR, ER and GR CALUX assays with baselines at EC0. 
Nevertheless, the repeatability of the anti-AR bioassay chromatogram 
was satisfactory: a negative peak of anti-androgenic activity was clearly 
seen in all triplicates at a retention time of 16.1  ±  0.2 min (CV1.4 %). 
The MRLs calculated for peaks in bioassay chromatograms are given 
in Table 1, part 1b. As there were considerable differences between 
assays in the experimental variation of the baseline response, the MRLs 
differ per assay. 
3.1.3. Consistency between bioassay chromatograms and MS results 
The repeatability of the fractionation was also assessed chemically 
by injecting a spiking mixture of 31 steroid hormones in triplicate on 
the UPLC-MS system. The compounds eluted between 9.2 and 17.0 min 
and maximum differences between RT triplicate values were 0.5 % 
(0.085 min). The acquired RTs and the CVs are given in Table S3, to-
gether with literature values for relative potencies of the compounds in 
the AR, ER and GR CALUX assays. The bioassay chromatograms that 
were recorded in triplicate in parallel for this mixture with AR, ER and 
GR CALUX are shown in Fig. 2. Most compounds in the mixture were 
detected in peaks of the bioassay chromatograms. Progestogens that 
lack sufficient cross reactivity on AR, ER and GR receptors were not 
visible in these assays. In addition, cortisone, prednisone and aldos-
terone had too little potency on the GR receptor to be detected in the 
GR CALUX assay at the tested concentrations (Relative potency <  
0.008 compared to dexamethasone; Table S3). Due to the fact that 
some compounds had RTs close to each other and that peak widths of 
single eluting compounds on this system were often > 0.3 min, co- 
elution of was observed e.g. for many glucocorticoids in the GR CALUX 
bioassay chromatogram and for 17α- and 17β-E2, estrone (E1) and 
ethynylestradiol (EE2) in the ER CALUX bioassay chromatogram. As 
can be seen in Fig. 2, a very good overlap was observed between the 
triplicate chromatograms with regard to peak RTs (CV ≤ 1.8 %, see 
Table 1 
(Anti-)androgenic, estrogenic and glucocorticoid activities (average +/− standard deviation) measured with CALUX bioassays 1.a.) negative (unspiked procedure 
blank) and positive (spiked) control samples and a surface water sample to determine recovery and repeatability in unfractionated extracts, 1.b. minimum reporting 
limits (MRL) of the peaks in bioassays chromatograms of the EDA-platform calculated from standard deviations in responses in the base lines and 2) activities in 
unfractionated extracts of field water samples. Activities in bold indicate attempts to identify responsible compounds with EDA.       
CALUX AR Anti-AR ERα GR  
ng DHT eq./l μg Flt eq./l pg E2- eq./l ng Dex. eq./l  
1.a. Method evaluation bioassay in unfractionated extract    
controls     
negative control (replicate 1, 2 and 3)  <  0.2  <  1.4  <  34  <  4.3 
repeatability and recovery positive control     
replicate 1 1.8  ±  0.6 29  ±  3 238  ±  22 259  ±  61 
replicate 2 1.5  ±  0.0 48  ±  12 161  ±  24 171  ±  5 
replicate 3 2.3  ±  0.9 42  ±  4 169  ±  33 133  ±  5 
average recovery pos. ctrl (%) 80  ±  18 101  ±  25 77  ±  17 73  ±  25  
repeatability Lek Channel sample     
replicate 1  <  0.2 7.2  ±  1.0  <  34  <  4.3 
replicate 2  <  0.2 6.1  ±  0.2  <  34  <  4.3 
replicate 3  <  0.2 9.2  ±  0.9  <  34  <  4.3 
average activity Lek Channel sample  <  0.2 7.5  ±  1.6 (CV 21 %)  <  34  <  4.3  
1.b.Method evaluation bioassay in fractionated extract (bioassay chromatogram)   
MRL (% of max. induction by ref. compound) 5.8 17 (compared to 
ref.comp. DHT) 
46 11 
2. Field study      
samples (unfractioned extract)     
Enclosed Meuse  <  0.2 72  ±  5 ∼ 26  ±  2  <  34*  <  4.3 
Reclaimed Land  <  0.2 10  ±  0 424  ±  17  <  4.3 
Lek Channel  <  0.2 9.2  ±  0.9  <  34  <  4.3 
Lake IJssel  <  0.2 7.4  ±  0.3  <  34  <  4.3 
WWTP effluent  <  0.2 11  ±  1 376  ±  19 40  ±  5 
* Value between LOD and LOQ.  
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Table S4) and peak surface (total average peak surfaces were AR: 
8.5  ±  1.8; ER: 129.2  ±  10.7 and GR: 119.4  ±  10.5 min*activity). 
The high repeatability of the fractionation and consistency between 
the peaks in the bioassay chromatograms and detected by MS indicate 
that the bioassay chromatograms can indeed be used to direct the 
identification process in EDA, and that only the MS data within small 
RT window around bioassay peaks have to be interpreted in the search 
for the causative compounds. 
3.2. Application of EDA platform to water samples 
3.2.1. Unfractionated extracts 
The total (anti)-androgenic, estrogenic and glucocorticoid activities 
measured in unfractionated extracts of the water samples are shown in  
Table 1, part 2. All activity types, except androgenic, were observed in 
the WWTP effluent. This is in line with earlier work in which removal of 
androgenic activity to undetectable levels in effluent of the same WWTP 
was observed whereas anti-AR, ER and GR were still detected in ef-
fluent (Houtman et al., 2018). Also other studies investigating muni-
cipal WWTPs reported reduction or removal of androgenic activity in 
the treatment, and the presence of anti-androgenic and estrogenic ac-
tivity in effluent (Bain et al., 2014; Itzel et al., 2020). 
The anti-androgenic activity (11  ±  0) ng Flt eq/L) was below the 
EBTs for ecological risk of Van der Oost et al. (van der Oost et al., 
2017b) and Escher et al. (2018) (25 and 14.4 μg Flt eq/L respectively). 
The estrogenic activity in effluent (376  ±  19 pg E2 eq/L) was within 
the range of the EBTs published for the ecological risks of this type of 
activity (between 0.1 and 0.4 ng E2-eq/L) Escher et al. (2018); van der 
Oost et al., 2017b; Jarošová et al., 2014). This indicates that – without 
further dilution in receiving waters- this effluent might lead to estro-
genic effects in the ecosystem. The glucocorticoid activity (40  ±  5 ng 
Dex eq/L) was below the only available EBT for the ecological risk of 
glucocorticoid activity (100 ng Dex eq/L (van der Oost et al., 2017b). 
Estrogenic and anti-androgenic activities were detected in surface 
waters at abstraction points for DW production, whereas AR and GR 
activities were not. A higher estrogenic activity than at the other lo-
cations was found at the Reclaimed Land. Like in the WWTP effluent, 
the estrogenic activity in the Reclaimed Land water sample was in the 
range of the ecological EBTs. Concerning human health risk, the ac-
tivity was below the EBT published by (Brand et al. (2013)) (3.8 ng E2 
eq/L), but higher than the values published by (Escher et al. (2015)) 
and proposed by Béen et al. (0.25 ng E2 eq/L; in preparation). At other 
surface water locations, estrogenic activity was below available EBTs. 
The highest anti-androgenic activity was found at the Enclosed Meuse. 
At this location, the anti-androgenic activity exceeded considerably the 
EBTs both for ecological (Escher et al., 2018; van der Oost et al., 2017b) 
and human health risks (Escher et al., 2018) and the value proposed by 
Béen et al. (2020, in preparation) of 4.8 μg Flt-eq/L. At other surface 
water locations, anti-androgenic activity was below available EBTs. 
In summary, ecological risks of anti-androgenic and estrogenic ac-
tivities cannot be excluded at some of the investigated locations. These 
activities exceed (some of the) EBTs for human health as well. However, 
it should be noticed that the drinking water companies using these 
locations as their sources apply advanced multi-barrier treatment 
technologies to remove organic pollutants - including those with en-
docrine disrupting potencies - to undetectably low levels or levels with 
negligible risks (Houtman, 2010). 
3.2.2. ER bioassay chromatograms 
Bioassay chromatograms were recorded for the water samples with 
the highest activities (WWTP, Enclosed Meuse and Reclaimed Land). 
Bioassay chromatograms for the WWTP effluent are presented in Fig. 3, 
those for the Enclosed Meuse and Reclaimed Land in Fig. S4 of the SI. 
A large peak of estrogenic activity was found between 13.9 and 
15.4 min in the WWTP bioassay chromatogram. Analysis of the MS-data 
did not lead to identification of the causative compound(s). However, 
Fig. 2. AR, ER and GR bioassay chromatograms of fractionated (n = 3), spotted and CALUX analysed mixture of steroid hormones. Small peaks related to spiked 
compounds indicated in Table 1 are annotated even if they were detected below the respective MRL. 
C.J. Houtman, et al.   Environmental Toxicology and Pharmacology 80 (2020) 103460
6
from many studies it is known that the natural estrogens 17α- and 17β- 
E2, E1 and the synthetic estrogen and contraceptive EE2 are wide-
spread in the aquatic environment. They are excreted by humans and 
cattle and as such predominantly emitted by WWTPs (Johnson et al., 
2000; Petrovic et al., 2002) and farm land run-off (Johnson et al., 
2006). They appear to be responsible for the estrogenic activity at many 
locations and in many matrices (Purdom et al., 1994; Houtman et al., 
2006, 2007; Houtman et al., 2004b). As the retention times of these 
estrogens are RT = 14.20 min (17β-E2), 14.40 (EE2), 14.57 (17α-E2), 
and 14.90 min (E1; Table S3), it is very likely that the large estrogenic 
peak observed in the bioassay chromatogram of the WWTP effluent is a 
co-elution of the mentioned estrogenic steroids. The estrogenic bioassay 
chromatograms of the Enclosed Meuse and Reclaimed Land (Fig. S4) 
also show peaks around RT = 14 min, endorsing the tentative identifi-
cation of these compounds. The fact that the estrogens were not iden-
tified by the high resolution MS can be explained by the much higher 
sensitivity for steroid estrogens in the ERα CALUX bioassay. The very 
low concentration (0.4 ng EEQ/L in the unfractionated extract) already 
evokes a clear response in the bioassay but is too low to be visible in the 
NTS mode of the HRMS used. 
3.2.3. GR bioassay chromatograms 
Six distinctive peaks were found in the bioassay chromatogram of 
the glucocorticoid activity. The high resolution of the fractionation in 
our HT-EDA platform thus indicates that at least six different com-
pounds contributed to the glucocorticoid activity. Similarity in RTs 
with compounds from the standard mixture was observed for pre-
dnicarbate (RT = 16.2 min) and rimexolone (RT = 17.0 min, Table S3). 
These are pharmaceuticals prescribed, respectively, to treat skin and 
eye inflammations. The presence of glucocorticoids in WWTP effluents 
has been reported earlier (Houtman et al., 2018; Zwart et al., 2020;  
Schriks et al., 2010). And using EDA, it often appeared difficult to 
identify all responsible compounds (Zwart et al., 2020; Hashmi et al., 
2020). 
Probably due to the same sensitivity issue as for estrogens, the MS 
failed to tentatively identify candidate compounds for the other four 
peaks. In this study, unidentified peaks were detected in the last part of 
the bioassay chromatogram (RT 18.0–20.2 min). As mentioned above, it 
is often observed that glucocorticoid activity is not fully removed 
during (conventional) wastewater treatment. These peaks might be 
caused by glucocorticoids that are either not degraded or absorbed in 
the WWTP, or they might consist of active metabolites of glucocorti-
coids formed during treatment (Zwart et al., 2020). In the future, we 
will investigate this by comparing bioassay chromatograms of samples 
of the different steps of the WWTP. The bioassay chromatograms of the 
surface water sites (Fig. S4) did not show any peaks of glucocorticoid 
activity. This is in line with the absence of glucocorticoid activity in the 
corresponding unfractionated extracts. 
3.2.4. Anti-AR bioassay chromatograms 
The anti-androgenic bioassay chromatogram of the WWTP sample 
showed a negative peak at 16.3–16.6 min. The androgenic bioassay 
chromatogram showed a small androgenic peak (that was not further 
identified) at 16.9 min. This latter activity must have been masked by 
the anti-androgenic activity in the unfractionated extract. Fractionation 
thus helped separating agonistic and antagonistic compounds, which 
are not observed in whole samples due to mutually counteracting ac-
tivities (Weiss et al., 2009). Analysis of the MS data in the time window 
16.3–16.6 min revealed a compound with an accurate mass of 307.1451 
amu; this mass and six most abundant fragments were uploaded in 
MetFrag, leading to tebuconazole as single hit (KEGG database). Con-
sequently, we tested this azole fungicide as pure standard, and the RT 
was confirmed on the MS to be 16.3 min, and as such the RT matched 
with that of the bioassay chromatogram peak. A concentration series of 
tebuconazole was tested in the anti-AR and cytotox CALUX bioassays 
and the concentration-response curves are shown in Fig. 4. 
Fig. 3. bioassay chromatograms of the WWTP effluent sample for estrogenic and glucocorticoid activity left) and (anti)-androgenic activity (right). Tentatively 
identified compounds are annotated at the corresponding RTs (min). The hormones were identified according to the corresponding RT, tebuconazole was tentatively 
identified based on RT and mass spectrum similarity. 
Fig. 4. Concentration-response series of tebuconazole in the anti-AR CALUX bioassay (left) and the cytotox (right) CALUX bioassays. Tebuconazole shows anti- 
androgenic activity and at a ∼100 times higher concentration also cytotoxicity. 
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Tebuconazole proved to be anti-androgenic with an EC50 of 4.4  ±  0.1 
μM and a REP of 0.13  ±  0.01 compared to that of Flt (left panel). This 
is in line with findings of Seeger et al. (2016) who found and EC10 of 
0.9 μM for tebuconazole in the anti-AR CALUX and of Christen et al. 
(2014) who found an EC50 of 6.86 μM in the human mammary gland 
cancer cell line MDA-kb2. Tebuconazole appeared to be cytotoxic at 
concentrations > 10−4 M (Fig. 4, right panel). This means that its anti- 
androgenic activity is apparent at much lower concentrations (∼100- 
fold) than its cytotoxicity, indicating that the inhibition of signal by the 
sample extract in the anti-AR CALUX is due to real antagonism on the 
AR, and as such that tebuconazole is confirmed as anti-androgen in the 
WWTP effluent extract. Many environmental contaminants, including 
polychlorinated biphenyls (Hamers et al., 2011), pesticides (Aït-Aïssa 
et al., 2010) and pharmaceuticals (e.g. Flt), are known to have anti- 
androgenic potencies. Propiconazole - an azole fungicide just like the 
now identified tebuconazole – was identified in surface water in former 
demonstration studies with the EDA platform (Zwart et al., 2018). 
The anti-AR bioassay chromatogram of the Enclosed Meuse (Fig. S4) 
showed a negative peak at 16.1 min, which was in line with the anti- 
androgenic activity in the unfractionated extract (Table 1). Analysis of 
MS data at this RT identified fatty acids and sulfonic acids that are 
unlikely to interfere with the AR receptor but also capsaïcin. This 
component of chilli pepper was found to induce degradation and in-
activation of the AR in prostate cancer cells (Zheng et al., 2015). 
However, a dilution series of the pure compound did not show anti- 
androgenic activity in the anti-AR CALUX at concentrations up to 
3*10−4 M (Fig. S5). Therefore, the compound does not explain the anti- 
androgenic activity in the Enclosed Meuse, and the real driver of the 
anti-androgenic activity at this location remains to be elucidated. 
The anti-androgenic bioassay chromatogram of the Reclaimed Land 
did not show a clear negative peak, indicating that the anti-androgenic 
activity in the unfractionated extract of this sample might e.g. have 
been due to multiple compounds with low individual activities that, 
also considering the high biological variation in the baseline of the 
bioassay chromatogram, did not evoke significant negative peaks. 
3.3. Workflow for the application of the platform in a routine monitoring 
context 
Water boards, DW companies, and governments put large efforts in 
monitoring chemical water quality. For a long time, chemical water 
quality monitoring has relied on chemical target analysis alone. This is 
mainly due to the fact that water quality legislation often requires 
target compound analysis methods for chemical monitoring as well as 
due to the analytical state of the art. However, there are too many 
contaminants in the aquatic environment to be monitored individually. 
Moreover, many possibly relevant compounds are unknown and as such 
cannot be incorporated in target methods (Brack et al., 2016). The 
really important question in risk assessment is if the water is safe for 
humans and the ecosystem, and not whether we can create a virtually 
complete list of all present compounds with their concentrations. For-
tunately, a paradigm shift from ‘compound’ based to ‘risk’ based mon-
itoring is currently ongoing. The 2015 update of the European Drinking 
water Council Directive 98/83/EC Annex II grants a certain degree of 
flexibility in performing the regular monitoring. Member States are 
allowed to derogate from their monitoring programs, provided credible 
risk assessments are performed. This opens the door for the im-
plementation of bioassays and screening techniques to focus on the most 
relevant drivers of chemical risk at each water body functioning as DW 
source. Concerning the Water Frame Work Directive, the target analysis 
of priority compounds is still compulsory, however, the selection of 
sites with the highest contaminant risks can be done by alternative 
methods, e.g. using an effect-based approach using bioassays and EBTs 
(Escher et al., 2018; Brack et al., 2017) as for example in the smart 
integrated monitoring (SIMONI) strategy for environmental risk as-
sessment (van der Oost et al., 2017b). 
Hence, bioassays and screening will play a more prominent role in 
(the design of) future risk-based monitoring programs (Brack et al., 
2016; Houtman et al., 2011), with EDA as the ultimate combination to 
focus on and prioritise compounds driving risks. Chemical target ana-
lysis will still be applied for the dedicated and quantitative monitoring 
of specific groups of compounds of particular interest, but will play a 
Fig. 5. Schematic representation of the position of analytical approaches in risk based monitoring of chemical water quality and the workflow of EDA as proposed for 
a routine monitoring context. In this workflow, EDA is split up in phases (blue boxes). Depending on the research question and the results obtained, it can be decided 
if only phase 1 (bioassay monitoring in unfractionated samples) or more phases of the platform, eventually aiming at full identification of active compounds, need to 
be performed. 
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less prominent role. The position of analytical approaches in a risk- 
based monitoring program is shown schematically in the “Analytical 
approaches” in Fig. 5. 
The at-line fractionation with a spotting device as incorporated in 
our EDA platform has made EDA much less time-consuming than the 
‘classic’ manual EDA approaches. However, performing a full EDA 
study is still time and cost intensive. We therefore propose a workflow 
by which EDA is split into phases and the information created by each 
phase is exploited to the maximum. In this way, depending on the re-
search question, it may not always be necessary to proceed through all 
steps of the platform. The workflow is represented in the “Workflow 
EDA” in Fig. 5, and is elaborated in sections 3.3.1 to 3.3.4. 
3.3.1. Phase 1: bioassay monitoring 
Bioassays are more and more used to monitor water quality for 
compounds with biological activities. In a routine monitoring context, 
initially only the bioassay measurements in the unfractionated extract 
will suffice. If measured bioassay responses exceed an EBT and the 
causative compounds are unknown, continuation with phase 2 is 
needed for both human and environmental risk assessment. It can also 
be decided to continue with phase 2 if the activity is  <  EBT and spe-
cific questions arise that may be answered by bioassay chromatograms 
(see 3.3.2). One such question might arise if there are both agonistic 
and antagonistic compounds in the sample that mutually mask each 
other’s activities to a combined level  <  EBT. 
The division of EDA phases is already incorporated in the SIMONI 
strategy for environmental risk assessment (van der Oost et al., 2017b). 
Tier 1 of this strategy assumes that the risks are low if no EBT ex-
ceedances are observed in a battery of relevant in vivo and in vitro 
bioassays. In that case no additional research is required. In cases where 
EBT exceedances indicate increased environmental risks, SIMONI ap-
plies target analysis of specific groups of organic substances (tier 2) and 
phases 2–4 of the EDA workflow to elucidate the drivers. 
3.3.2. Phase 2: bioassay chromatogram determination 
The second phase of the EDA workflow is the fractionation and 
recording of bioassay chromatograms. Simultaneously, MS data are 
recorded, although they do not have to be analysed or interpreted yet in 
this phase. They can be archived and used for (retrospective) analysis in 
later phases of the workflow. The bioassay chromatogram itself already 
provides valuable information to characterize the drivers of the ob-
served effect. Due to the high resolution of the fractionation, com-
pounds elute over multiple fractions, generating a peak of several data 
points for each compound, although co-elution may lead to some 
overlap. This means that the number of peaks represents the 
(minimum) number of compounds contributing to the observed ac-
tivity. In addition, if both agonistic and antagonistic modes are re-
corded, the bioassay chromatograms show the presence of agonistic 
compounds whose effects are masked by antagonistic compounds in the 
non-fractionated extracts (and vice versa). Moreover, the RTs of the 
peaks indicate the polarity of the compounds (or any other principle the 
chromatographic separation was based upon). 
By plotting overlays, bioassay chromatograms can be used to mu-
tually compare samples taken at different sites. By recording bioassay 
chromatograms at a single site over time, variations in water compo-
sition regarding a specific activity can be investigated. By recording 
chromatograms after several water treatment steps, fate of the effects in 
treatment plants can be followed. If it is necessary to identify re-
sponsible compounds, continuation to the next phase(s) is needed. 
3.3.3. Phase 3: tentative identification of known culprits 
The most time-consuming phase of the platform is the NTS identi-
fication (phase 4). However, as was demonstrated in the field study for 
estrogens and certain glucocorticoids, some suspects may already be 
found in the bioassay chromatogram. They can be tentatively identified 
by their known RTs and added to a suspect list. Sometimes this is the 
only possible way of identification, because for certain compounds 
(such as highly potent steroids) the NTS is not sensitive enough to de-
tect the low amounts that cause activity in the bioassays. In those cases 
that the drivers of the effect are fully unknown, phase 4 is entered. 
3.3.4. Phase 4: HRMS identification of unknown compounds by NTS and 
confirmation 
NTS is gaining strength to identify compounds (Hollender et al., 
2017). A large advantage of application of NTS in the context of EDA is 
that the interpretation, the most time-intensive part of NTS, exclusively 
has to be done within the RT-window in which the peak of interest 
eluted. As seen in section 3.1, we obtained an excellent consistency 
between the RTs of peaks in the bioassays chromatogram and MS data. 
Only features within a small window of 0.1−0.2 min around the RT of 
the bioassay peak will have to be interpreted. NTS in the context of 
EDA, however, is no guarantee for success: in our study tebuconazole 
was successfully identified in the WWTP effluent, but the anti-andro-
genic activity in the Meuse sample could not be addressed. Generally, 
identification will be especially challenging for the more ‘promiscuous’ 
effects, such as anti-androgenicity and e.g. pregnane X receptor acti-
vation, for which a wide variety of compounds in the environment may 
be responsible. For such endpoints the chance is small that specific 
culprits can be denoted beforehand, so NTS is essential. The NTS 
technique is still developing rapidly, so its potency will expectedly in-
crease further in the near future. 
4. Conclusion 
The developed high resolution, high throughput EDA platform used 
in this study enables characterisation and identification of biologically 
active compounds in water samples. The performance evaluation 
showed that the EDA platform is robust, delivers very repeatable results 
and excellent consistency between the bioassay chromatograms and MS 
results. 
The application of the platform to field samples led to the tentative 
identification of estrogens, anti-androgens and glucocorticoids in was-
tewater treatment plant effluent and surface water samples, although 
not all bioassay peaks could be assigned to their causative compounds. 
The field study demonstrated that a full identification and con-
firmation of the drivers of the biological activity is not needed in all 
cases to characterize the active compounds present. Even without the 
MS results the bioassay chromatograms give extensive added informa-
tion, e.g. they inform us about the active compounds in terms of po-
larity (low or high RT), number and activity of contributing compounds 
(number of peaks and peak area). These aspects are used in the work-
flow that is proposed for the application of the EDA platform in a 
routine monitoring context. As such, the EDA platform is a valuable tool 
for the investigation of unknown compounds with biological activity, 
both in an academic setting as in the context of legislative, govern-
mental or routine monitoring. 
CRediT authorship contribution statement 
Corine J. Houtman: Conceptualization, Methodology, Formal 
analysis, Resources, Writing -original draft, Visualization, Supervision, 
Project administration, Funding acquisition. R. ten Broek: 
Methodology, Software, Validation, Investigation. Y. van Oorschot: 
Validation, Investigation, Visualization. D. Kloes: Validation, 
Investigation. R. van der Oost: Writing - review & editing. M. Rosielle: 
Validation, Investigation. M.H. Lamoree: Writing - review & editing. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to 
C.J. Houtman, et al.   Environmental Toxicology and Pharmacology 80 (2020) 103460
9
influence the work reported in this paper. 
Acknowledgements 
This study was performed by assignment of the Dutch drinking 
water companies Dunea, PWN and Waternet. Waternet is acknowledged 
for the possibility to sample at one of its WWTPs. The authors are in-
debted to Nick Zwart, Eelco Pieke and Bram Veefkind for their valuable 
contributions. BioDetection systems B.V. is acknowledged for providing 
the AR, ER, GR and cytotox CALUX cell lines. 
Appendix A. Supplementary data 
Supplementary material related to this article can be found, in the 
online version, at doi:https://doi.org/10.1016/j.etap.2020.103460. 
References 
Aït-Aïssa, S., Laskowski, S., Laville, N., Porcher, J.-M., Brion, F., 2010. Anti-androgenic 
activities of environmental pesticides in the MDA-kb2 reporter cell line. Toxicol. Vitr. 
24 (7), 1979–1985. 
Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., 
et al., 2010. Adverse outcome pathways: a conceptual framework to support eco-
toxicology research and risk assessment. Environ. Toxicol. Chem. Int. J. 29 (3), 
730–741. 
Bain, P.A., Williams, M., Kumar, A., 2014. Assessment of multiple hormonal activities in 
wastewater at different stages of treatment. Environ. Toxicol. Chem. 33 (10), 
2297–2307. 
Brack, W., Ait-Aissa, S., Burgess, R.M., Busch, W., Creusot, N., Di Paolo, C., et al., 2016. 
Effect-directed analysis supporting monitoring of aquatic environments–An in-depth 
overview. Sci. Total Environ. 544, 1073–1118. 
Brack, W., Dulio, V., Ågerstrand, M., Allan, I., Altenburger, R., Brinkmann, M., et al., 
2017. Towards the review of the European Union Water Framework Directive: re-
commendations for more efficient assessment and management of chemical con-
tamination in European surface water resources. Sci. Total Environ. 576, 720–737. 
Brand, W., de Jongh, C.M., van der Linden, S.C., Mennes, W., Puijker, L.M., van Leeuwen, 
C.J., et al., 2013. Trigger values for investigation of hormonal activity in drinking 
water and its sources using CALUX bioassays. Environ. Int. 55, 109–118. 
Christen, V., Crettaz, P., Fent, K., 2014. Additive and synergistic antiandrogenic activities 
of mixtures of azol fungicides and vinclozolin. Toxicol. Appl. Pharmacol. 279 (3), 
455–466. 
Ehrlich, S., Lambers, D., Baccarelli, A., Khoury, J., Macaluso, M., Ho, S.-M., 2016. 
Endocrine disruptors: a potential risk factor for gestational diabetes mellitus. Am. J. 
Perinatol. 33 (13), 1313–1318. 
Escher, B.I., Allinson, M., Altenburger, R., Bain, P.A., Balaguer, P., Busch, W., et al., 2014. 
Benchmarking organic micropollutants in wastewater, recycled water and drinking 
water with in vitro bioassays. Environ. Sci. Technol. 48 (3), 1940–1956. 
Escher, B.I., Neale, P.A., Leusch, F.D., 2015. Effect-based trigger values for in vitro 
bioassays: reading across from existing water quality guideline values. Water Res. 81, 
137–148. 
Escher, B.I., Aїt-Aїssa, S., Behnisch, P.A., Brack, W., Brion, F., Brouwer, A., et al., 2018. 
Effect-based trigger values for in vitro and in vivo bioassays performed on surface 
water extracts supporting the environmental quality standards (EQS) of the European 
Water Framework Directive. Sci. Total Environ. 628, 748–765. 
Hamers, T., Kamstra, J.H., Cenijn, P.H., Pencikova, K., Palkova, L., Simeckova, P., et al., 
2011. In vitro toxicity profiling of ultrapure non-dioxin-like polychlorinated biphenyl 
congeners and their relative toxic contribution to PCB mixtures in humans. Toxicol. 
Sci. 121 (1), 88–100. 
Hashmi, M.A.K., Krauss, M., Escher, B.I., Teodorovic, I., Brack, W., 2020. Effect-directed 
analysis of progestogens and glucocorticoids at trace concentrations in river water. 
Environ. Toxicol. Chem. 39 (1), 189–199. 
Heindel, J.J., Newbold, R., Schug, T.T., 2015. Endocrine disruptors and obesity. Nat. Rev. 
Endocrinol. 11, 653. 
Hollender, J., Schymanski, E.L., Singer, H.P., Ferguson, P.L., 2017. Nontarget screening 
with high resolution mass spectrometry in the environment: ready to go? ACS 
Publications. 
Houtman, C.J., 2010. Emerging contaminants in surface waters and their relevance for 
the production of drinking water in Europe. J. Integr. Environ. Sci. 7 (4), 271–295. 
Houtman, C.J., Cenijn, P.H., Hamers, T., Lamoree, M.H., Legler, J., Murk, A.J., et al., 
2004a. Toxicological profiling of sediments using in vitro bioassays, with emphasis 
on endocrine disruption. Environ. Toxicol. Chem. 23 (1), 32–40. 
Houtman, C.J., Van Oostveen, A.M., Brouwer, A., Lamoree, M.H., Legler, J., 2004b. 
Identification of estrogenic compounds in fish bile using bioassay-directed fractio-
nation. Environ. Sci. Technol. 38 (23), 6415–6423. 
Houtman, C.J., Booij, P., Jover, E., Pascual del Rio, D., Swart, K., van Velzen, M., et al., 
2006. Estrogenic and dioxin-like compounds in sediment from Zierikzee harbour 
identified with CALUX assay-directed fractionation combined with one and two di-
mensional gas chromatography analyses. Chemosphere 65 (11), 2244–2252. 
Houtman, C.J., Booij, P., van der Valk, K.M., van Bodegom, P.M., van den Ende, F., 
Gerritsen, A.A., et al., 2007. Biomonitoring of estrogenic exposure and identification 
of responsible compounds in bream from Dutch surface waters. Environ. Toxicol. 
Chem. 26 (5), 898–907. 
Houtman, C.J., Legler, J., Thomas, K.V., 2011. Effect-directed analysis of endocrine dis-
ruptors in aquatic ecosystems. In: Brack, W. (Ed.), Effect-Directed Analysis of 
Complex Environmental Contamination. The Handbook of Environmental Chemistry. 
Springer Verlag, 15. Berlin-Heidelberg, pp. 237–266. 
Houtman, C.J., ten Broek, R., Brouwer, A., 2018. Steroid hormonal bioactivities, culprit 
natural and synthetic hormones and other emerging contaminants in waste water 
measured using bioassays and UPLC-tQ-MS. Sci. Total Environ. 630, 1492–1501. 
Houtman, C.J., Kroesbergen, J., Baggelaar, P.K., van Lieverloo, J.H.M., 2019. Statistical 
analysis of a large set of semi-quantitative GC–MS screening data to evaluate and 
prioritize organic contaminants in surface and drinking water of the Netherlands. Sci. 
Total Environ., 133806. 
Itzel, F., Baetz, N., Hohrenk, L.L., Gehrmann, L., Antakyali, D., Schmidt, T.C., et al., 2020. 
Evaluation of a biological post-treatment after full-scale ozonation at a municipal 
wastewater treatment plant. Water Res. 170, 115316. 
Jarošová, B., Bláha, L., Giesy, J.P., Hilscherová, K., 2014. What level of estrogenic activity 
determined by in vitro assays in municipal waste waters can be considered as safe? 
Environ. Int. 64 (Supplement C), 98–109. 
Jobling, S., Nolan, M., Tyler, C.R., Brighty, G., Sumpter, J.P., 1998. Widespread sexual 
disruption in wild fish. Environ. Sci. Technol. 32 (17), 2498–2506. 
Johnson, A.C., Belfroid, A., Di Corcia, A., 2000. Estimating steroid oestrogen inputs into 
activated sludge treatment works and observations on their removal from the ef-
fluent. Sci. Total Environ. 256 (2-3), 163–173. 
Johnson, A.C., Williams, R.J., Matthiessen, P., 2006. The potential steroid hormone 
contribution of farm animals to freshwaters, the United Kingdom as a case study. Sci. 
Total Environ. 362 (1-3), 166–178. 
Jonker, W., Lamoree, M.H., Houtman, C.J., Hamers, T., Somsen, G.W., Kool, J., 2015. 
Rapid activity-directed screening of estrogens by parallel coupling of liquid chro-
matography with a functional gene reporter assay and mass spectrometry. J. 
Chromatogr. A 1406, 165–174. 
Jonker, W., Ballesteros-Gómez, A., Hamers, T., Somsen, G.W., Lamoree, M.H., Kool, J., 
2016. Highly selective screening of estrogenic compounds in consumer-electronics 
plastics by liquid chromatography in parallel combined with nanofractionation- 
bioactivity detection and mass spectrometry. Environ. Sci. Technol. 50 (22), 
12385–12393. 
Jonker, W., de Vries, K., Althuisius, N., van Iperen, D., Janssen, E., ten Broek, R., et al., 
2019. Compound Identification Using Liquid Chromatography and High-resolution 
Noncontact Fraction Collection With a Solenoid Valve. SLAS TECHNOLOGY: 
Translating Life Sciences Innovation 2472630319848768. 
Kabir, E.R., Rahman, M.S., Rahman, I., 2015. A review on endocrine disruptors and their 
possible impacts on human health. Environ. Toxicol. Pharmacol. 40 (1), 241–258. 
Luigi, R., 2011. Bioassays as a tool for evaluating advanced oxidation processes in water 
and wastewater treatment. Water Res. 45 (15), 4311–4340. 
Macova, M., Toze, S., Hodgers, L., Mueller, J.F., Bartkow, M., Escher, B.I., 2011. 
Bioanalytical tools for the evaluation of organic micropollutants during sewage 
treatment, water recycling and drinking water generation. Water Res. 45 (14), 
4238–4247. 
Neale, P.A., Antony, A., Bartkow, M.E., Farre, M.J., Heitz, A., Kristiana, I., et al., 2012. 
Bioanalytical assessment of the formation of disinfection byproducts in a drinking 
water treatment plant. Environ. Sci. Technol. 46 (18), 10317–10325. 
Neale, P.A., Altenburger, R., Aït-Aïssa, S., Brion, F., Busch, W., de Aragão Umbuzeiro, G., 
et al., 2017. Development of a bioanalytical test battery for water quality monitoring: 
fingerprinting identified micropollutants and their contribution to effects in surface 
water. Water Res. 123, 734–750. 
Petrovic, M., Sole, M., de Alda, M.J.L., Barcelo, D., 2002. Endocrine disruptors in sewage 
treatment plants, receiving river waters, and sediments: integration of chemical 
analysis and biological effects on feral carp. Environ. Toxicol. Chem. 21 (10), 
2146–2156. 
Petrovic, M., Gonzalez, S., Barcelo, D., 2003. Analysis and removal of emerging con-
taminants in wastewater and drinking water. Trac-Trends Analytical Chem. 22 (10), 
685–696. 
Petrovic, M., Gros, M., Barcelo, D., 2006. Multi-residue analysis of pharmaceuticals in 
wastewater by ultra-performance liquid chromatography-quadrupole-time-of-flight 
mass spectrometry. J. Chromatogr. A 1124 (1-2), 68–81. 
Purdom, C.E., Hardiman, P.A., Bye, V.J., Eno, N.C., Tyler, C.R., Sumpter, J.P., 1994. 
Estrogenic effects of effluents from sewage treatment works. Chem. Ecol. 8, 275–285. 
Schriks, M., van Leerdam, J.A., Van der Linden, S.C., Van Der Burg, B., van Wezel, A.P., 
De Voogt, P., 2010. High-resolution mass spectrometric identification and quantifi-
cation of glucocorticoid compounds in various wastewaters in the Netherlands. 
Environ. Sci. Technol. 44 (12), 4766–4774. 
Schriks MB, K., Simon, E., Besselink, H., Van der Linden, S., Kienle, C., Van der Burg, B., 
hebert, A., 2015. Selection Criteria to Select in Vitro Bioassays for Implementation 
and Use. 
Seeger, B., Klawonn, F., Bekale, B.N., Steinberg, P., 2016. The ability of the YAS and AR 
CALUX assays to detect the additive effects of anti-androgenic fungicide mixtures. 
Toxicol. Lett. 241, 193–199. 
Stefanakis AIB, J.A., 2015. Review of emerging contaminants in Water: classification, 
sources and potential risks. Impact of Water Pollution on Human Health and 
Environment Sustainability: IGI Global. 
Sumpter, J.P., 2005. Endocrine disrupters in the aquatic environment: An overview. Acta 
Hydrochim. Hydrobiol. 33 (1), 9–16. 
Sumpter, J.P., Jobling, S., 2013. The occurrence, causes, and consequences of estrogens in 
the aquatic environment. Environ. Toxicol. Chem. 32 (2), 249–251. 
Touraud, E., Roig, B., Sumpter, J.P., Coetsier, C., 2011. Drug residues and endocrine 
disruptors in drinking water: Risk for humans? Int. J. Hyg. Environ. Health 214 (6), 
C.J. Houtman, et al.   Environmental Toxicology and Pharmacology 80 (2020) 103460
10
437–441. 
van der Linden, S.C., von Bergh, A.R., van Vught-Lussenburg, B.M., Jonker, L.R., Teunis, 
M., Krul, C.A., et al., 2014. Development of a panel of high-throughput reporter-gene 
assays to detect genotoxicity and oxidative stress. Mutat. Res. Genet. Toxicol. 
Environ. Mutagen. 760, 23–32. 
Van der Linden, S.C., Heringa, M.B., Man, H.Y., Sonneveld, E., Puijker, L.M., Brouwer, A., 
et al., 2008. Detection of multiple hormonal activities in wastewater effluents and 
surface water, using a panel of steroid receptor CALUX bioassays. Environ. Sci. 
Technol. 42 (15), 5814–5820. 
van der Oost, R., Sileno, G., Janse, T., Nguyen, M.T., Besselink, H., Brouwer, A., 2017a. 
SIMONI (Smart Integrated Monitoring) as a novel bioanalytical strategy for water 
quality assessment: part II–field feasibility survey. Environ. Toxicol. Chem. 36 (9), 
2400–2416. 
van der Oost, R., Sileno, G., Suárez-Muñoz, M., Nguyen, M.T., Besselink, H., Brouwer, A., 
2017b. SIMONI (Smart Integrated Monitoring) as a novel bioanalytical strategy for 
water quality assessment: Part I–model design and effect-based trigger values. 
Environ. Toxicol. Chem. 36 (9), 2385–2399. 
van Wezel, A., Mons, M., van Delft, W., 2010. New methods to monitor emerging che-
micals in the drinking water production chain. J. Environ. Monit. 12 (1), 80–89. 
Weiss, J.M., Hamers, T., Thomas, K.V., Van Der Linden, S., Leonards, P.E., Lamoree, M.H., 
2009. Masking effect of anti-androgens on androgenic activity in European river 
sediment unveiled by effect-directed analysis. Anal. Bioanal. Chem. 394 (5), 
1385–1397. 
Weiss, J., Simon, E., Stroomberg, G., de Boer, R., de Boer, J., van der Linden, S., et al., 
2011. Identification strategy for unknown pollutants using high-resolution mass 
spectrometry: androgen-disrupting compounds identified through effect-directed 
analysis. Anal. Bioanal. Chem. 400 (9), 3141–3149. 
Zheng, L., Chen, J., Ma, Z., Liu, W., Yang, F., Yang, Z., et al., 2015. Capsaicin causes 
inactivation and degradation of the androgen receptor by inducing the restoration of 
miR-449a in prostate cancer. Oncol. Rep. 34 (2), 1027–1034. 
Zwart, N., Nio, S.L., Houtman, C.J., de Boer, J., Kool, J., Hamers, T., et al., 2018. High- 
throughput effect-directed analysis using downscaled in vitro reporter gene assays to 
identify endocrine disruptors in surface water. Environ. Sci. Technol. 52, 11. 
Zwart, N., Jonker, W., Rt, Broek, de Boer, J., Somsen, G., Kool, J., et al., 2020. 
Identification of mutagenic and endocrine disrupting compounds in surface water 
and wastewater treatment plant effluents using high-resolution effect-directed ana-
lysis. Water Res. 168, 115204.  
C.J. Houtman, et al.   Environmental Toxicology and Pharmacology 80 (2020) 103460
11
